Compounded Tirzepatide vs Mounjaro: 2026 Price and Access Compared

Last reviewed: September 21, 2026 Last updated: September 21, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

PlexusDx publishes this comparison and is one of the providers discussed. We use the same evidence rules for our own program and competing programs.

The short answer

Compounded tirzepatide from U.S. telehealth programs costs $249–$399 per month on transparent month-to-month plans; branded Mounjaro or Zepbound through telehealth channels runs $299–$1,498 per month for the medication, with some programs adding separate monthly membership fees of $74–$149. The all-in recurring cost for branded tirzepatide typically lands between $448 and $1,498 per month, depending on the provider, dose tier, and membership structure. Compounded tirzepatide is not FDA-approved and is prepared by licensed compounding pharmacies under state and federal oversight; branded Mounjaro and Zepbound are FDA-approved for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). This guide normalizes the recurring economics, explains the regulatory and practical differences, and maps which access path fits which scenario—cash budget, insurance benefit design, dose availability, and tolerance for supply or approval uncertainty.

At-a-glance: compounded tirzepatide vs branded Mounjaro/Zepbound

Capture dates: PlexusDx, Found, Eden, MEDVi, Ro, LifeMD, OrderlyMeds September 4–21, 2026; Levity September 4, 2026. All figures verified at provider checkout or pricing pages. Three-month and six-month prepaid rates shown where available; total recurring uses month-to-month membership tier where applicable.

Normalized like-for-like: month-to-month recurring cost over 12 months

Month-to-month plans reveal the true cost without upfront commitment. The table below calculates total first-year outlay—accounting for introductory rates where they exist and labeling every derived figure.

Capture dates as above. All effective monthly figures and 12-month totals are our calculation. MEDVi and Levity first-month figures are advertised introductory rates; all subsequent months billed at the standard refill rate. Eden and LifeMD first-month figures reflect advertised introductory membership fees paired with the standard refill rate.

For comparison, PlexusDx six-month prepaid tirzepatide injection costs $249 per month ($1,494 for six months, our calculation), which annualizes to $2,988 over 12 months if renewed at the same rate (our calculation)—a $480 annual saving versus the month-to-month plan and $1,320 below Found's cash monthly total (our calculation).

Regulatory and quality differences: FDA-approved vs compounded

Mounjaro and Zepbound are FDA-approved formulations of tirzepatide manufactured by Eli Lilly. Mounjaro is approved for type 2 diabetes; Zepbound for chronic weight management in adults with obesity or overweight plus weight-related comorbidity. Both undergo FDA review for safety, effectiveness, and manufacturing quality, and both carry FDA-mandated labeling, including a boxed warning about thyroid C-cell tumors observed in rodent studies.

Compounded tirzepatide is prepared by state-licensed compounding pharmacies—typically 503A facilities that compound patient-specific prescriptions. Compounded medications are not FDA-approved. FDA does not review compounded drugs before marketing for safety, effectiveness, or quality. A licensed clinician determines whether a prescription is appropriate for an individual patient. Compounding pharmacies operate under state pharmacy board oversight and must follow United States Pharmacopeia (USP) standards for sterile compounding (USP <797>), but the final product does not carry FDA approval or batch-to-batch pre-market review.

PlexusDx works with licensed 503A compounding pharmacies.

The practical trade-off: branded Mounjaro and Zepbound offer FDA manufacturing oversight, consistent labeling, and established pharmacovigilance; compounded tirzepatide offers materially lower cost and often simpler access when insurance prior authorization proves prohibitive, but without the same regulatory pre-market review.

Access pathways and insurance dynamics

Branded Mounjaro and Zepbound list prices exceed $1,000 per month at retail. Manufacturer savings cards historically reduced patient cost to $25 per month for commercially insured, eligible patients, but coverage policies vary widely: many plans now require step therapy (trial of other agents first), prior authorization, or exclude GLP-1 receptor agonists for weight management entirely. When prior authorization is denied or the plan excludes the drug, the telehealth cash price—$299–$1,498 per month for medication, plus potential membership fees—becomes the effective rate.

Compounded tirzepatide bypasses prior authorization because it is not billed through insurance. The patient pays cash, the provider writes the prescription, and a compounding pharmacy prepares and ships the medication. This path eliminates insurer gatekeeping but also forfeits any insurance benefit or manufacturer coupon. For individuals whose plan does not cover GLP-1s for weight loss, or whose deductible or copay exceeds $289–$399 per month, compounded tirzepatide often delivers lower out-of-pocket cost.

Found offers an insurance-support pathway: the $199 per month service fee (or $99 per month on the annual prepaid plan, captured September 4, 2026) includes clinician visits and prior-authorization support, with the medication billed separately to insurance. If prior authorization succeeds and the plan covers branded tirzepatide, the patient pays the plan's copay (often $25–$50 per month) plus the Found service fee; if the request is denied, Found transitions to compounded medication included in the service fee. This hybrid model suits individuals with coverage but uncertain approval odds.

Dose availability and titration

Branded Mounjaro and Zepbound are dispensed in pre-filled, single-dose pens at fixed strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg once weekly. The manufacturer labeling specifies a titration schedule starting at 2.5 mg for four weeks, then 5 mg for four weeks, with further increases as tolerated. Pens are packaged in cartons of four (one month's supply).

Compounded tirzepatide is typically supplied in multi-dose vials or, at some providers, oral capsules. Injectable compounded tirzepatide allows the prescriber to specify intermediate or custom doses—useful when a patient experiences intolerable side effects at the next pen strength or when more gradual titration improves adherence. Oral compounded tirzepatide (offered by Henry Meds, PlexusDx, and others) bypasses injection entirely, though absorption and dose data for oral formulations remain limited compared to the extensively studied subcutaneous route.

Programs with dose-agnostic pricing (PlexusDx, Embody, MEDVi) charge the same monthly rate regardless of strength, simplifying budgeting during titration. Programs with per-dose pricing (Mochi Health, Amble) raise the monthly cost as the patient advances to higher maintenance doses.

Supply continuity and shortage considerations

As of September 2026, tirzepatide has intermittently appeared on and been removed from the FDA drug shortage list. When a drug is in shortage, FDA exercises enforcement discretion permitting compounding pharmacies to prepare copies of that drug under section 503A; when the shortage resolves, that discretion typically ends, and compounding the commercially available product may face legal constraint. Branded Mounjaro and Zepbound supply has generally stabilized at most retail and mail-order pharmacies, though allocation and backorder occasionally occur for specific pen strengths.

For patients prioritizing uninterrupted therapy, this dynamic matters: compounded tirzepatide access depends partly on ongoing shortage status, and supply changes can force a switch to branded product (if insurance covers it) or a different compounded GLP-1. Branded product access depends on manufacturer production, wholesaler allocation, and pharmacy inventory—historically more predictable than compounding-channel supply once a shortage declaration lifts.

Choose compounded tirzepatide if…

• Your insurance does not cover GLP-1 receptor agonists for weight management, or prior authorization was denied and the appeal timeline exceeds your treatment window.
• Your out-of-pocket cost for branded Mounjaro or Zepbound—whether cash price or post-deductible copay—exceeds $289–$399 per month, and you accept the trade-off of compounded (non-FDA-approved) medication for the cost saving.
• You prefer month-to-month flexibility without long-term contracts or large upfront payments, and you value transparent, dose-agnostic pricing that will not increase as you titrate.
• You experienced side effects at a standard pen strength and your clinician recommends an intermediate dose not available in the branded product line.
• You want to avoid injection and are willing to try an oral formulation, understanding that oral tirzepatide data remain more limited than the established subcutaneous evidence base.

Choose branded Mounjaro or Zepbound if…

• Your insurance plan covers the medication with prior authorization, your request was approved, and your copay plus any program fee is at or below the compounded alternative.
• You prioritize FDA manufacturing oversight, batch testing, and the pharmacovigilance infrastructure that accompanies an approved drug.
• You value the convenience and dosing precision of pre-filled, single-use pens over drawing from a vial.
• You are comfortable navigating prior authorization, appeal processes, and potential insurer step-therapy requirements in exchange for the regulatory assurance of an FDA-approved product.
• Supply continuity is a top priority and you want to minimize the risk of formulary or legal changes affecting compounded availability.

Where PlexusDx fits

PlexusDx offers compounded tirzepatide injection at $289 per month month-to-month, $269 per month on a three-month plan, and $249 per month on a six-month plan—medication, clinician access, unlimited support, and shipping included, with no separate membership fee and the same price at every dose. We also offer compounded tirzepatide oral capsules at $349 per month month-to-month, $299 per month on a three-month plan, and $279 per month on a six-month plan, for patients who prefer to avoid injection. All plans allow cancellation without penalty.

PlexusDx works with licensed 503A compounding pharmacies. A licensed provider reviews your intake, medical history, and goals; if a tirzepatide prescription is appropriate, we send it to the pharmacy, and your first shipment typically arrives within seven business days. If your situation changes—side effects emerge, dose adjustment is needed, or you want to pause—message your care team at any time; responses typically come within one business day.

We publish this comparison because we believe transparency about pricing structure, regulatory status, and trade-offs helps patients make better decisions—even when another program's model or price point fits better. If insurance covers branded Mounjaro or Zepbound at a lower net cost than $289 per month and you value FDA approval, pursue that path. If prior authorization failed, your plan excludes weight-management GLP-1s, or your deductible makes branded product unaffordable, compounded tirzepatide may deliver the clinical benefit at a sustainable price.

PlexusDx holds a 4.3-star rating on Trustpilot, with 79% of reviews at five stars and 83% at four stars or higher (captured September 9, 2026; trustpilot.com/review/plexusdx.com).

Service-quality snapshot: review themes across programs

Review data captured September 4–9, 2026, from Trustpilot:

• PlexusDx: 4.3 stars, 79% five-star, 83% four-star or higher. Common positive themes: fast shipping, responsive care team, clear pricing. Negative reports cite occasional delays in provider response during high-volume periods.
• Found: 4.1 stars, approximately 732 reviews. Positive themes: insurance navigation support, structured program. Negative themes: confusion over separate medication and service billing, perceived difficulty canceling annual plans.
• Henry Meds: 4.4 stars, approximately 13,000 reviews. Positive themes: reliable oral-formulation delivery, straightforward process. Negative themes: limited injection options (oral-only tirzepatide path).
• Eden: 4.5 stars, approximately 5,000 reviews. Positive themes: comprehensive support, coaching integration. Negative: one captured 1-star review reported an 11-day order delay and repeated requests for records Eden had previously issued (September 4, 2026).
• MEDVi: 4.3 stars, approximately 15,000 reviews. Positive themes: fast onboarding, clear communication. Negative themes: introductory-to-refill price jump ($279 first month to $399 refill) surprises some users who expected consistent pricing.
• Mochi Health: 4.5 stars, approximately 18,000 reviews. Positive themes: low starting-dose price, flexible dose adjustments. Negative themes: per-dose pricing model raises monthly cost significantly at higher maintenance doses.
• OrderlyMeds: 3.6 stars, approximately 634 reviews. Negative themes captured in 1-star and 2-star reviews: fast charging but slow refunds, non-response to inquiries, delayed shipping, unannounced pharmacy changes, unwanted calls and texts after opt-out requests (September 4, 2026).
• Fridays Health: 4.2 stars, approximately 4,700 reviews. Mixed themes: competitive multi-month pricing, but some confusion over which advertised rate applies at checkout.
• Ro (branded Zepbound): Rating not captured; Trustpilot profile exists. Negative themes from reviews: confusing separate membership and medication costs, prior-authorization friction, customer-service hold times, perceived weak efficacy (individual reports, not clinical claims).
• WeightWatchers Clinic (branded pathways): 4.0 stars, 4,646 reviews across all services. Negative themes: annual or six-month lock-in, reports of charges after attempted cancellation, insurance denials, slow or absent clinical communication (September 4, 2026).

These are individual reports and user allegations captured at a single point in time; they do not establish that any program's service is systematically unreliable, only that some users have reported these experiences on public review platforms.

Prepaid and annual-plan economics

Several programs discount the per-month rate in exchange for upfront payment:

• Found (cash annual): $2,028 paid upfront for 12 months of compounded tirzepatide, which works out to $169 per month (our calculation; captured September 4, 2026). Compare to $359 per month on the cash monthly plan—an annual saving of $2,280 if you complete the full year (our calculation).
• Found (insurance-support annual): $1,188 paid upfront for 12 months of service, which works out to $99 per month (our calculation; captured September 4, 2026), plus medication copays. Compare to $199 per month on the monthly insurance-support plan.
• PlexusDx (six-month injection): $249 per month ($1,494 total; our calculation) versus $289 per month month-to-month—a six-month saving of $240 (our calculation).
• Ro (Body Program six-month): $534 paid upfront for six months of membership, which works out to $89 per month (our calculation), plus medication cost of $299–$449 per dose tier, for a total of $388–$538 per month effective (our calculation; captured September 4, 2026). Compare to $448–$598 per month on the monthly plan (our calculation).
• AltRx (12-month): $125 per month on a 12-month commitment, versus $149 per month month-to-month (captured September 4, 2026); advertised promotion stated to end September 5, 2026—confirm current rates at checkout.

Prepaid plans carry commitment risk: if you experience intolerable side effects, your clinician discontinues the medication, or your goals change, most programs do not refund unused months. Confirm the cancellation and refund policy in writing before prepaying.

Methodology and freshness

We captured pricing and service details from provider websites, checkout flows, and Trustpilot profiles between July 20 and September 21, 2026. Every price figure is accompanied by its capture date and source. Where a provider displays conflicting rates across pages or between advertised and checkout figures, we note the conflict and advise confirming at the point of purchase. Figures labeled "our calculation" derive from published rates (e.g., dividing a prepaid total by the number of months, or summing medication and membership fees); we never derive prices by applying discounts or promotions not explicitly published. Review ratings and themes are reported as individual user allegations or aggregated platform data, not as verified facts about service quality. This article will be refreshed when we observe material pricing changes, new regulatory guidance on compounding, or shifts in branded-product availability.

Frequently Asked Questions

Is compounded tirzepatide the same medication as Mounjaro or Zepbound?

No. Compounded tirzepatide is prepared by a compounding pharmacy and is not FDA-approved; Mounjaro and Zepbound are FDA-approved tirzepatide products manufactured by Eli Lilly. Compounded medications are not reviewed by FDA before marketing for safety, effectiveness, or quality, and they may differ in formulation, excipients, concentration, and delivery device from the branded product.

Can I use insurance to pay for compounded tirzepatide?

Typically no. Most insurance plans do not cover compounded medications, and compounding pharmacies generally do not bill insurance directly. Compounded tirzepatide is a cash-pay service. Some programs, such as Found's insurance-support plan, help you pursue prior authorization for branded medication while offering compounded as a fallback if the request is denied.

How much does branded Mounjaro or Zepbound cost without insurance?

Retail list price exceeds $1,000 per month. Through telehealth channels, cash prices range from $299 per month (Ro, LifeMD starting dose, medication only) to $1,498 per month (OrderlyMeds all-inclusive pen), often plus separate monthly membership fees of $74–$149. Manufacturer savings cards may reduce cost to $25 per month for eligible commercially insured patients, but card terms and plan coverage vary.

What happens if the tirzepatide shortage ends and compounding is no longer allowed?

If FDA removes tirzepatide from the drug shortage list and ends enforcement discretion, compounding pharmacies may be required to stop preparing tirzepatide copies. Your provider would then need to transition you to branded Mounjaro or Zepbound (if your insurance covers it) or an alternative GLP-1 receptor agonist. Some programs communicate contingency plans; confirm yours before starting treatment.

Do PlexusDx tirzepatide plans require a contract or minimum commitment?

No. PlexusDx month-to-month tirzepatide plans ($289/month injection, $349/month oral) allow cancellation at any time with no penalty. Three-month and six-month prepaid plans offer lower per-month rates in exchange for upfront payment; if you cancel mid-term, remaining months are not refunded, so choose the plan length that matches your confidence in continuing therapy.

Sources

• PlexusDx tirzepatide pricing and service details, plexusdx.com/products/tirzepatide-injection and /products/tirzepatide-oral, captured September 21, 2026.
• Found pricing (compounded tirzepatide cash monthly $359, annual $169/month effective prepaid, insurance-support monthly $199, annual $99/month effective prepaid), found.com pricing page, captured September 4, 2026.
• Eden pricing (medication $199/month, membership $39 first month then $99/month), eden.com, captured September 4, 2026.
• MEDVi pricing (first month $279, refill $399), medvi.com checkout flow, captured September 4, 2026.
• Ro Body Program and Zepbound pricing (medication $299–$449/month, membership $149/month or $89/month six-month prepaid), ro.co pricing page, captured September 4, 2026.
• LifeMD Zepbound vial pricing (medication $299/month starting dose, membership $39 first month then $149/month), lifemd.com, captured September 4, 2026.
• OrderlyMeds Zepbound pen pricing ($1,498/month), orderlymeds.com, captured September 4, 2026.
• Levity Mounjaro pricing ($1,249 first month, $1,299 refill), levity.com, captured September 4, 2026.
• Henry Meds oral tirzepatide pricing ($297/month for 3-month supply, $891 total), henrymeds.com, captured September 4, 2026.
• Mochi Health compounded tirzepatide starting dose ($90/month medication, $39/month membership), mochihealth.com, captured September 4, 2026.
• BrightMeds, AltRx, Amble, Remedy Meds, Willow, ShedRx, Fridays Health, TrimRx, Peak Wellness, Embody, 10Rx tirzepatide pricing, respective provider websites and checkout flows, captured July 20–September 4, 2026.
• Trustpilot ratings and review themes: PlexusDx (trustpilot.com/review/plexusdx.com, 4.3 stars, captured September 9, 2026); Found (4.1 stars, ~732 reviews); Henry Meds (4.4 stars, ~13K reviews); Eden (4.5 stars, ~5K reviews); MEDVi (4.3 stars, ~15K reviews); Mochi Health (4.5 stars, ~18K reviews); OrderlyMeds (3.6 stars, ~634 reviews); Fridays Health (4.2 stars, ~4.7K reviews); Remedy Meds (4.7 rating displayed during intake); WeightWatchers Clinic (4.0 stars, 4,646 reviews); all captured September 4, 2026 from respective Trustpilot profiles.
• FDA drug shortage database and compounding enforcement discretion guidance, fda.gov, accessed September 2026.
• Mounjaro and Zepbound prescribing information (dosing, indications, boxed warning), accessed via DailyMed September 2026.

Compounded medication disclosure: Compounded medications are not FDA-approved. FDA does not review compounded drugs before marketing for safety, effectiveness, or quality. A licensed clinician determines whether a prescription is appropriate for an individual patient. PlexusDx works with licensed 503A compounding pharmacies.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.